Mutated NGF Polypeptide for Ophthalmic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ophthalmic disorders, particularly those affecting the optic nerve and retinal ganglion cells, lack effectiveness and are associated with undesirable side effects such as pain, and there is a need for a therapeutic agent that can be administered with sufficient yield and purity to treat these conditions without adverse effects.
Innovation Solution
A polypeptide with a mutation in the human nerve growth factor (NGF) sequence, specifically a substitution of arginine at position 100 with glutamic acid, is used for the treatment and prevention of ophthalmic disorders, characterized by reduced nociceptive activity and administered topically or intravitreally to the eye, with a preferred dosage and formulation to ensure efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant human NGF (rhNGF) is administered to treat optic nerve damage, then RGC viability is improved, but pain and adverse effects occur
Solution Approach 1:
The invention segments the NGF molecule by introducing specific mutations (P61S and R100E) that separate its neurotrophic function from its nociceptive function. The P61S mutation preserves TrkA receptor binding for RGC survival while the R100E mutation eliminates p75 receptor binding that mediates pain, effectively dividing the molecule's functions into independent controllable elements
Solution Approach 2:
The invention applies local quality changes by modifying specific amino acid positions (61 and 100) within the NGF sequence while maintaining the overall structure. The P61S mutation locally alters the TrkA interaction interface to preserve neuroprotection, while R100E locally modifies the p75 binding site to eliminate pain, creating region-specific functional properties within the same molecule
2Adaptability or versatility
If treatment is delayed after optic nerve damage, then clinical relevance increases, but therapeutic effectiveness decreases
Solution Approach 1:
The mutated NGF (P61S/R100E) is designed to be administered preliminarily after optic nerve damage occurs, rather than requiring immediate administration. The molecule is engineered to maintain stability and effectiveness during the delayed administration window, allowing clinical application while preserving therapeutic benefit through its enhanced pharmacokinetic properties
Solution Approach 2:
The invention changes the molecular parameters of NGF through site-directed mutagenesis at positions 61 and 100. These parameter changes (amino acid substitutions) fundamentally alter the molecule's receptor interaction profile, enabling it to maintain neurotrophic activity while eliminating nociceptive effects, thereby allowing delayed administration without loss of efficacy
3Manufacturing precision
If pure rhNGF is administered, then therapeutic purity is improved, but pain and inflammation occur
Solution Approach 1:
The invention converts the harmful inflammatory and nociceptive properties of pure NGF into beneficial effects by mutating the molecule. The R100E mutation specifically eliminates the pro-inflammatory and pain-inducing interactions with p75 and TRPV1 receptors, while the P61S mutation preserves neuroprotective functions, thereby transforming a harmful pure substance into a beneficial therapeutic agent
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
The present invention provides a non-natural polypeptide for use in treatment and/or prevention of an ophthalmic disorder in a mammalian subject. Administration of the polypeptide is well tolerated by the mammal. The non-natural polypeptide is provided at high purity.